Christophe Durand joined the Paris office of The Boston Consulting Group in 1998 and moved to the New York office three years later. He is a core member of the Health Care practice, with deep industry experience in medtech and biopharma generics. He is also a global topic leader in growth and innovation in medtech.

Christophe has direct experience in multiple medtech and life science segments, including large equipment, clinical supplies, orthopedics, cardiac, general surgery, critical care, and emergency medicine.

In 2010, Christophe led BCG's medtech R&D benchmark of 30 participants across sectors and coauthored the resulting article in In Vivo.

Christophe was a key member of the team that managed the integration of Mylan and Merck Generics in 2007 and 2008. He has also been involved in a number of other topics (such as strategy for injectables, commercial effectiveness, and general and administrative optimization) with several generics clients.